Enabling innovation for under-researched infectious diseases

Calls for proposals

Calls for proposals

  • Governing Board Evaluation Dates

    The Governing Board members will meet twice during 2019 to review new proposals. Proposals need to be submitted 6 weeks prior to the GB evaluation date.

    • 2nd April
    • 10th October

    Call open all year.

    Please visit "Submit project Proposal”, where you will find the documents we are asking you to complete to apply for a TCOLF grant.


    IN ADDITION TO TUBERCULOSIS, MALARIA, KINETOPLASTIDS AND ENTERIC INFECTIONS, The Tres Cantos Open Lab Foundation invites applications for projects with a focus on prevention and/or treatment of EED

    BACKGROUND: EED, an incompletely defined subclinical inflammatory disorder of the small intestine, is emerging as one of the underlying cause of stunting and may explain at least 40% of all cases of stunting even after controlling for diarrhoea and is associated with reduced efficacy of enteric vaccines in developing countries. The condition, is thought to be a result of living in unsanitary conditions, under-nutrition and ingestion of faecal bacteria and is characterized by the flattening of villi, increase in crypt depth, reduction of absorptive capacity of the small intestine and reduced barrier function resulting in bidirectional leakage of fluid, bacteria and toxins across the gut wall.1,2


    SCIENTIFIC OPPORTUNITY: Current health and nutrition programmes are having a limited impact to mitigate EED effects. TCOLF is looking for innovative opportunities to complement these strategies. These opportunities include but are not limited to pre/pro-biotics, hits/leads and drug assets (marketed or in development) that exploit the pathophysiology of EED.

    About this call—Key areas of interest:

    • Exploitation of new targets towards EED treatment
    • Phenotypic in vitro assays that allow identification of hits (single cell, co-culture, organoids, etc)
    • Medicinal chemistry optimisation of hits/leads
    • Animal models that allow evaluation and establishment of PK/PD relationships
    • Biopharmaceutical/microbiome-based approaches

    More information about TCOLF
    Ballell, L. et al. Nat Rev Drug Discov, 15, 292 (2016)